REG - Uniphar PLC - Navi acquisition not cleared by CCPC

UnipharAnnouncement

16/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221216:nRSP9160Ja&default-theme=true

RNS Number : 9160J  Uniphar PLC  16 December 2022

Navi acquisition not cleared by CCPC

Dublin, London | 16 December 2022: Uniphar plc today announces that the Irish
Competition and Consumer Protection Commission ("CCPC") has not cleared the
proposed acquisition of Irish-headquartered pharmacy services group Navi Group
("Navi").

Following the proposal to acquire Navi, which was announced on 23(rd) December
2021, both Uniphar and Navi have engaged extensively with the CCPC and
supported them in their review of the proposed transaction. However, the
transaction will now no longer proceed to completion.

Navi has been a longstanding partner of Uniphar and both parties will continue
to work closely together to support our shared customer base of independent
community pharmacies.

 

For further details contact:

 Uniphar                                                                      +353 (0) 1 428 7777
 Allan Smylie
 Head of Strategy and IR                                                      investor.relations@Uniphar.ie (mailto:investor.relations@Uniphar.ie)

 Davy (Joint Corporate Broker, Nominated Adviser and Euronext Growth Listing  +353 (0) 1 679 6363
 Sponsor)
 Barry Murphy
 Niall Gilchrist
 Lauren O'Sullivan

 RBC Capital Markets (Joint Corporate Broker)                                 +44 (0) 20 7653 4000
 Jonathan Hardy
 Jamil Miah

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)                      +44 (0) 20 7710 7600
 Matt Blawat
 Ben Maddison
 Francis North

 Q4 PR                                                                        +353 (0) 1 475 1444 or
 (Public Relations Adviser to Uniphar)                                        +353 87 235 6461
 Iarla Mongey

 

 

 

About Uniphar plc

 

Headquartered in Dublin, Ireland, the Uniphar Group is an international
diversified healthcare services business servicing the requirements of more
than 200 multinational pharmaceutical and medical technology manufacturers
across three divisions - Commercial & Clinical, Product Access and Supply
Chain & Retail. The Group is active in Ireland, the UK, Europe, the US and
Australia.

The Company's vision is to improve patient access to pharmaco-medical products
and treatments by enhancing connectivity between manufacturers and healthcare
stakeholders. Uniphar represents a strong combination of scale, growth, and
profitability.

 

Commercial & Clinical

In Commercial & Clinical, the Group provides outsourced sales, marketing
& distribution solutions to multinational pharmaceutical and medical
device manufacturers. Active in Ireland, the UK, Benelux, the Nordics, Germany
and the US, the Group is growing with its clients to provide pan-European
solutions, with a targeted service offering in the US. Uniphar has built fully
integrated digitally enabled customer centric solutions that are supported by
our highly experienced and clinically trained teams, leveraging our digital
technology and insights which allows us to deliver consistently exceptional
outcomes for our clients.

 

Product Access

In Product Access, the Group is growing two distinct service offerings: 1) "On
Demand", which are pharmacy led solutions for sourcing and supplying
unlicensed medicines to meet the needs of both retail and hospital
pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions
for controlling the release of speciality medicines for specifically approved
patient populations in agreed markets. The Group currently delivers product
access solutions on a global basis.

 

Supply Chain & Retail

Uniphar is an established market leader in Ireland with c. 53% market share in
the wholesale/hospital market, supported by a network of 381 owned, franchised
and symbol group pharmacies. The business supports the diverse customer base
through the provision of strong service levels coupled with innovative
commercial initiatives. Supply Chain & Retail is an Irish only business
for the Group, although the manufacturer relationships and infrastructure are
also utilised for the benefit of the Commercial & Clinical and Product
Access divisions

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQGPGCWPUPPGRA